TMCnet News

Zika Virus Opportunities And Threats - Research and Markets
[June 20, 2016]

Zika Virus Opportunities And Threats - Research and Markets


Research and Markets has announced the addition of the "Anti-Infective Drug News Issue 339" report to their offering.

As well as a number of smaller developers looking to carve a niche for themselves, we would expect the most prominent vaccine developers to focus on Zika vaccine research. The travel vaccine market would provide an element of profitability, but regional brand establishment will be a more significant draw. The lack of prophylactic options should not immediately impact Brazil's tourist industry, but this year's big events will act as a test case, guiding future travel advice.

Key Topics Covered:

  1. Zika Virus Opportunities And Threats
  2. FDA Accepts Teflaro sNDA For Filing
  3. MGB Biopharma/UoS To Co-Develop Novel MGB Anti-Infectives
  4. Telephus Secures Australian Patent Covering Therapeutic Abs For Staphylococcus Infections
  5. Bavarian Nordic Enters Research Collaboration To Develop MRSA Vacine
  6. Allergan/AstraZeneca Collaborate To Develop ATM-AVI Antibiotic
  7. Theravance Launches Vibativ In Canada
  8. Reaching Stakeholder Consensus Key To Tackling AMR Threat
  9. VAXEM Hib Approved In Japan
  10. FDA Approves Updated Dalvance Dosing
  11. Cidara's CD101 IV Gains FDA ODD For Candidaemia/Invasive Candidiasis
  12. SCYNEXIS' Antifungal Receives FDA Fast Track and QIDP Designations
  13. Aurobindo Gains FDA Voriconazole Approval
  14. FDA Approves Harvoni For HCV Patients With Advanced Liver Disease
  15. Health Canada Accepts Sitavig NDA For Review
  16. Protein Sciences/UNIGEN To Source (News - Alert) Flublok From Japan
  17. FDA Approves Expanded Use Of Daklinza
  18. Valneva/GSK Enter R&D Collaboration For EB66 Cell Line
  19. Merck's Zepatier Approved In Canada
  20. Sanofi Pasteur Targeting Zika Vaccine
  21. GeoVax To Develop Zika Vaccine
  22. GSK Seeks US Approval For Expanded Use Of FluLaval Quadrivalent
  23. NewLink Genetics To Develop New Zika Treatment Options
  24. UniSA Partners With Biotech Company To Develop Zika Vaccine
  25. FDA Approves Merck's Fixed-Dose HCV Regimen
  26. EC Approves Expanded Use Of Daklinza
  27. Region To Remain Vulnerable To Zika
  28. Zika Outbreak Poses Diagnostic Opportunity
  29. Gilead In Strong Position To Counter TAF Lawsuit
  30. Gilead To Target (News - Alert) Transformational Opportunities
  31. Dynamics Within Industry-Academia Partnerships Changing


For more information visit http://www.researchandmarkets.com/research/xdqgbf/antiinfective



[ Back To TMCnet.com's Homepage ]